New $25 million boost helps Synageva get down to business of good medicine
This article was originally published in Scrip
Executive Summary
Synageva BioPharma CEO Sanj K Patel said he has always held to the philosophy that good medicine is good business. And with the new $25 million in private equity his firm's investors ponied up this week, they obviously believe privately held Synageva is on the right development path to bring that good medicine to the marketplace, with the potential to provide a solid return on their investment.